Cliff Asness's CTKB Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 912,342 shares of Cytek Biosciences, Inc. (CTKB) worth $3.99 M, representing 0.00% of the portfolio. First purchased in 2022-Q3, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in CTKB, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 585,116 shares. Largest reduction occurred in Q4 2025, reducing 276,435 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Cytek Biosciences (CTKB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cytek Biosciences (CTKB) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +168,887 | Add 22.72% | 912,342 | $4.37 |
| Q4 2025 | -276,435 | Reduce 27.10% | 743,455 | $5.05 |
| Q3 2025 | -218,503 | Reduce 17.64% | 1.02 M | $3.47 |
| Q2 2025 | +585,116 | Add 89.57% | 1.24 M | $3.40 |
| Q1 2025 | +521,135 | Add 394.37% | 653,277 | $4.01 |
| Q4 2024 | +52,236 | Add 65.37% | 132,142 | $6.49 |
| Q3 2024 | +19,759 | Add 32.85% | 79,906 | $5.54 |
| Q2 2024 | +40,240 | Add 202.14% | 60,147 | $5.58 |
| Q1 2024 | -36,299 | Reduce 64.58% | 19,907 | $6.71 |
| Q4 2023 | +17,167 | Add 43.97% | 56,206 | $9.12 |
| Q3 2023 | +13,057 | Add 50.25% | 39,039 | $5.52 |
| Q2 2023 | +25,982 | New Buy | 25,982 | $8.54 |
| Q4 2022 | -31,163 | Sold Out | 0 | $0.00 |
| Q3 2022 | +31,163 | New Buy | 31,163 | $14.73 |
Cliff Asness's Cytek Biosciences Investment FAQs
Cliff Asness first purchased Cytek Biosciences, Inc. (CTKB) in Q3 2022, acquiring 31,163 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Cytek Biosciences, Inc. (CTKB) for 14 quarters since Q3 2022.
Cliff Asness's largest addition to Cytek Biosciences, Inc. (CTKB) was in Q2 2025, adding 1,238,393 shares worth $4.21 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 912,342 shares of Cytek Biosciences, Inc. (CTKB), valued at approximately $3.99 M.
As of the Q1 2026 filing, Cytek Biosciences, Inc. (CTKB) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Cytek Biosciences, Inc. (CTKB) was 1,238,393 shares, as reported at the end of Q2 2025.